Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barré syndrome

Abstract

Pniifrd in Bel~iiiiii -a// right.i resened Copyighr 0 Munksgourd IY 94 4CTA NEUROLOGICA SCANDINAVICA value of cerebrospinal fluid neuron-specific enolase and S-lOOb protein in Guillain-Barre syndrome. Acta Neurol Scand 1994: 89: 27-30. 0 Munksgaard 1994.We measured the cerebrospinal fluid (CSF) concentrations of neuron-specific enolase (NSE) and S-100b protein (S-100b) using enzyme immunoassay methods, in 24 patients with Guillain-Barre syndrome and 46 controls, and examined their prognostic values. Sixteen of 24 patients showed elevated levels ( > the mean + 2SD levels of controls) of NSE, S-IOOb, or both, and in those with higher NSE or S-100b levels there was a rather longer Material and methodsGBS pafients -Twenty-four patients (1 5 men and 9 women) aged 14 to 64years old (mean? SD,

Tumor necrosis factor-α, interleukin-1β, and interleukin-6 in the cerebrospinal fluid of patients with cervical myelopathy and lumbar radiculopathy

“…The highest possible JOA score-L is 29 points. The mean JOA score-L was 12.4 points (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. To evaluate the relationships between neurological deficits and the concentrations of the cytokines, the sum of motor disturbance and the sensory disturbance of JOA score-L (neurological deficits score) was calculated.…”

“…Lumbar radiculopathy results from compression of the nerve root by herniated disk material, osteophytes, and/or ligamentum flavum. Under these conditions, neural tissue damage can occur, and specific cytokines are produced from the nerve and glial cells, and released into the cerebrospinal fluid (CSF) [11,12,21,22]. Moreover, the cytokine concentration in the CSF is elevated by the increased permeability of the blood-nerve barrier caused by spinal degenerative disorders [1,26,27].…”

“…Many authors have studied the cytokines in the CSF of patients with neurologic diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, and transverse myelitis [11,12,21,22]; however, to our knowledge, there have been a few clinical reports [2,6] regarding the cytokines in the CSF of patients with spinal degenerative disorders such as cervical spondylotic myelopathy and lumbar canal stenosis.…”

Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects

“…This process allows for the study of 'biomarkers' in the CSF. [10][11][12][13] Although, several studies have been published concerning the use of biomarkers in CSF of patients with traumatic brain injury, only few studies exist in the field of SCI. 10 The potential of this approach in traumatic SCI was recently demonstrated by using the CSF concentration of several inflammatory cytokines and structural proteins such as S100b, tau and glial fibrillary acidic protein (GFAP) in patients within 24 h post injury.…”

Biomarkers in spinal cord injury

“…This process allows for the study of 'biomarkers' of SCI in the CSF. [10][11][12] A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal or pathologic processes or pharmacologic responses to a therapeutic intervention. 13 Biomarkers of SCI can be approached in two ways: (1) a direct survey of primary structural damage using a specific unique marker (or markers) of tissue damage, and (2) measure aspects of the cellular, biochemical or molecular cascades in the secondary injury (or repair) response phase.…”